RayKnowChina Research Map
Shortlist0

TianjinTianjin Medical University

Tianjin Medical University Cancer Institute & Hospital

天津医科大学肿瘤医院

Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Tianjin Medical University Cancer Institute & Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌7 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌47 papers led12 open trials led
  3. Hepatocellular carcinoma肝细胞癌88 papers led11 open trials led
  4. Stomach cancer胃癌78 papers led6 open trials led
  5. Hepatoblastoma肝母细胞瘤1 paper led
  6. Chordoma脊索瘤1 paper led
  7. Osteosarcoma骨肉瘤18 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  9. Neuroblastoma神经母细胞瘤21 papers led1 open trial led
  10. Ewing sarcoma尤文肉瘤1 paper led
  11. Multiple myeloma多发性骨髓瘤10 papers led1 open trial led
  12. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 7 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 1120242025: 112025

2 hospitals in Tianjin for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  2. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueSide effects & quality of lifeImaging & AI
Departments in papersRadiation oncologyMedical oncology
Papers it led7
  1. Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China.2025BMC medicineFree full text
  2. The impact of submandibular glands protection on xerostomia as monitored by diffusion-weighted imaging in nasopharyngeal carcinoma patients.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  3. Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. Traditional Chinese medicine formula 01 for nasopharyngeal carcinoma (NPC01) for head & neck cancer and health-related quality of life: a retrospective study.2022BMC complementary medicine and therapiesFree full text
  5. IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma.2022Journal of cellular and molecular medicineFree full text
  6. What is the appropriate skin cleaning method for nasopharyngeal cancer radiotherapy patients? A randomized controlled trial.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  7. MicroRNA-203a-3p affects the biological characteristics of nasopharyngeal carcinoma by targeting vascular endothelial growth factor-C.2021Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
All its trials on ClinicalTrials.gov, any status5
  1. Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal CarcinomaStatus unknownNCT04782765Lead sponsorPhase 2Start 2021-03
  2. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  3. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  4. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  5. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
More papers found outside PubMed (not counted)8
  1. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Researchconference-abstract
  2. Advancing Precise Diagnosis of Nasopharyngeal Carcinoma Through Endoscopy-Based Radiomics Analysis: Transitioning from Static Imaging to Video Analysis2024SSRN Electronic Journalpreprint
  3. Advancing Precise Diagnosis of Nasopharyngeal Carcinoma Through Endoscopy-Based Radiomics Analysis: Transitioning from Static Imaging to Video Analysis2024SSRN Electronic Journalpreprint
  4. Endoscopy-Based Radiomics Analysis for Precise Diagnosis of Nasopharyngeal Carcinoma: From Static Images to Video Analysis2024SSRN Electronic Journalpreprint
  5. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figsharedataset
  6. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.2022Journal of Clinical Oncologyconference-abstract
  7. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncologyconference-abstract
  8. Clustering of nasopharyngeal carcinoma intensity modulated radiation therapy plans based on k-means algorithm and geometrical features2021Internatuinal Journal of Radiation Researcharticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 47 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.6%.

Papers led
47
2021–2025
Trials led
24
any status, ClinicalTrials.gov
Open trials led
12
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 9920212022: 101020222023: 8820232024: 111120242025: 992025

2 hospitals in Tianjin for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 20

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07246330

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  2. Recruiting
    Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07457528

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  3. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

  4. Recruiting
    Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07038629

    Age 70 years to 90 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  5. Recruiting
    dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07162506

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  6. Recruiting
    Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06452602

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  7. Recruiting
    AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06489197

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  8. Recruiting
    Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
    Phase
    Phase 3
    Started
    2021-12
    Registry
    NCT04807673

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  9. Not yet recruiting
    Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07493993

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  10. Not yet recruiting
    Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07531979

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  11. Not yet recruiting
    Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07721103

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  12. Not yet recruiting
    Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06814158

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  13. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  14. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  15. Recruiting
    Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06342167

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesAnyang, Fuzhou, Taizhou, Tianjin, Xinxiang, Yinchuan

  16. Recruiting
    Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06637163

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin

  17. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

  18. Recruiting
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2019-09
    Registry
    NCT04135664

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin

  19. Not yet recruiting
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07769658

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou

  20. Not yet recruiting
    A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Registry
    NCT06136988

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyNeoadjuvant & combined treatmentRadiotherapy
Departments in papersRadiation oncologyMedical oncologyRadiology / nuclear medicineGastroenterology / hepatology
Papers it led47
  1. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical t2025BMC cancerFree full text
  2. Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma.2025BMC cancerFree full text
  3. Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial.2025CancerFree full text
  4. LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy.2025Cancer immunology, immunotherapy : CIIFree full text
  5. Immunochemotherapy plus radiotherapy versus immunochemotherapy alone as first-line treatment for treatment-naïve, advanced esophageal squamous cell carcinoma (AEC-ICR-1st): A multi-center cohort study.2025Cancer letters
  6. Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma.2025Cancer medicineFree full text
  7. Spectral CT-based nomogram for evaluation of neoadjuvant chemotherapy response in esophageal squamous cell carcinoma.2025European radiology
  8. IL-15 signaling via cis- and trans-presentation to progenitor-exhausted CD8+ T cells enhances radio-immunotherapy efficacy in ESCC.2025Journal of nanobiotechnologyFree full text
  9. Retrospective comparative study of video- and robot-assisted esophagectomy after neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.2025Surgical endoscopy
  10. Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma.2024BMC cancerFree full text
  11. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.2024Cancer
  12. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial.2024Cancer cell
  13. Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies.2024Cancer letters
  14. Neoadjuvant chemoimmunotherapy was associated with better short-term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy.2024Cancer medicineFree full text
  15. A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC.2024Cell death & diseaseFree full text
  16. Feasibility and Safety of PD-1 Blockades Among Elderly Patients with Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Study.2024Drug design, development and therapyFree full text
  17. Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature.2024Environmental toxicology
  18. Integrated machine learning developed a prognosis-related gene signature to predict prognosis in oesophageal squamous cell carcinoma.2024Journal of cellular and molecular medicineFree full text
  19. Neoadjuvant chemoimmunotherapy followed by robot esophagectomy has no effect on short-term results compared with surgery alone.2024Thoracic cancerFree full text
  20. Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma.2024World journal of gastroenterologyFree full text
  21. Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma.2023BMC cancerFree full text
  22. High expression of PPFIA1 in human esophageal squamous cell carcinoma correlates with tumor metastasis and poor prognosis.2023BMC cancerFree full text
  23. Establishment of a risk model by integrating hypoxia genes in predicting prognosis of esophageal squamous cell carcinoma.2023Cancer medicineFree full text
  24. USP4 promotes the proliferation, migration, and invasion of esophageal squamous cell carcinoma by targeting TAK1.2023Cell death & diseaseFree full text
  25. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.2023Frontiers in immunologyFree full text
  26. Effects of PEG in patients with esophageal squamous cell carcinoma during concurrent chemoradiotherapy: a prospective study.2023Gastrointestinal endoscopy
  27. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.2023Immunotherapy
  28. Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.2023Journal of leukocyte biology
  29. Comparison of clinicopathological features and prognostic significance between synchronous multiple primary and solitary esophageal squamous cell carcinomas.2022BMC cancerFree full text
  30. CXCR4 promotes the growth and metastasis of esophageal squamous cell carcinoma as a critical downstream mediator of HIF-1α.2022Cancer scienceFree full text
  31. Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  32. Comparison of dynamic changes in the peripheral CD8+ T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy.2022Frontiers in immunologyFree full text
  33. Single cell sequencing revealed the mechanism of PD-1 resistance affected by the expression profile of peripheral blood immune cells in ESCC.2022Frontiers in immunologyFree full text
  34. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.2022OncoimmunologyFree full text
  35. A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy.2022Radiation oncology (London, England)Free full text
  36. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A pha2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  37. Development and validation of nodal staging score in pN0 patients with esophageal squamous cell carcinoma: A population study from the SEER database and a single-institution cohort.2022Thoracic cancerFree full text
  38. Is adjuvant immunotherapy a new standard for non-pathological complete response patients with resectable esophageal squamous cell carcinoma?2022Thoracic cancerFree full text
  39. A nomogram to predict lymph node metastasis risk for early esophageal squamous cell carcinoma.2021BMC cancerFree full text
  40. The prognostic performance of the log odds of positive lymph nodes in patients with esophageal squamous cell carcinoma: A population study of the US SEER database and a Chinese single-institution cohort.2021Cancer medicineFree full text
  41. High-mobility group AT-hook 2 promotes growth and metastasis and is regulated by miR-204-5p in oesophageal squamous cell carcinoma.2021European journal of clinical investigation
  42. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.2021Frontiers in immunologyFree full text
  43. TGIF1 plays a carcinogenic role in esophageal squamous cell carcinoma through the Wnt/β‑catenin and Akt/mTOR signaling pathways.2021International journal of molecular medicineFree full text
  44. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study.2021OncoimmunologyFree full text
  45. Lymph node dissection around left recurrent laryngeal nerve: robot-assisted vs. video-assisted McKeown esophagectomy for esophageal squamous cell carcinoma.2021Surgical endoscopyFree full text
  46. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.2021The oncologistFree full text
  47. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation.2021TheranosticsFree full text
Chinese-language papers (not in the count)2
  1. [The influence of Ras-associated binding protein 23 knockdown on the migration and invasion of esophageal squamous cell carcinoma cells and its mechanism].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Research progress and challenges of neoadjuvant therapy for esophageal squamous cell carcinoma].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status50
  1. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Lead sponsorPhase 2Start 2026-07
  2. Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07721103Lead sponsorPhase 2Start 2026-07
  3. Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingNCT07246330Lead sponsorPhase 3Start 2026-03
  4. Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCRecruitingNCT07457528Lead sponsorPhase 2Start 2026-03
  5. Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07493993Lead sponsorPhase 2Start 2026-06
  6. Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2Not yet recruitingNCT07531979Lead sponsorPhase 2Start 2026-04
  7. Chemoradiation Plus Iparomlimab Consolidation in Older With ESCCRecruitingNCT07038629Lead sponsorPhase 2Start 2025-09
  8. Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal CancerNot yet recruitingNCT06814158Lead sponsorPhase 2Start 2025-03
  9. dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction ChemoimmunotherapyRecruitingNCT07162506Lead sponsorPhase 2Start 2025-11
  10. Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.RecruitingNCT06452602Lead sponsorPhase 2Start 2024-06
  11. AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT06489197Lead sponsorPhase 2Start 2024-11
  12. Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)RecruitingNCT04807673Lead sponsorPhase 3Start 2021-12
  13. Tislelizumab Plus Concurrent Chemoradiation in Older With ESCCStatus unknownNCT06061146Lead sponsorPhase 2Start 2023-10
  14. Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell CarcinomaStatus unknownNCT05449483Lead sponsorPhase 2Start 2022-05
  15. A Phase II Study of CRT Combined With QL1706 in ESCC PatientsStatus unknownNCT05490719Lead sponsorPhase 2Start 2022-08
  16. Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05476380Lead sponsorPhase 2Start 2021-02
  17. An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 AntibodyStatus unknownNCT04866381Lead sponsorPhase 2Start 2021-04
  18. Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)Status unknownNCT04389177Lead sponsorPhase 2Start 2020-07
  19. Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell CarcinomaStatus unknownNCT05637268Lead sponsorPhase 2Start 2020-11
  20. To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing ChemoradiotherapyCompletedNCT04199832Lead sponsorStart 2019-12
  21. Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCCStatus unknownNCT03671265Lead sponsorN/AStart 2018-09
  22. Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.CompletedNCT06190652Lead sponsorStart 2018-10
  23. Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCCCompletedNCT03222440Lead sponsorN/AStart 2017-07
  24. The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell CarcinomaCompletedNCT06241066Lead sponsorStart 2014-01
  25. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  26. Standardized MRI and Structured Reporting for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07769658Study siteStart 2026-09
  27. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  28. Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Study sitePhase 2Start 2024-10
  29. Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell CarcinomaRecruitingNCT06342167Study sitePhase 2Start 2024-03
  30. A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.Not yet recruitingNCT06136988Study sitePhase 1/Phase 2Start 2023-12
  31. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Study siteStart 2022-07
  32. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell CarcinomaRecruitingNCT04135664Study sitePhase 3Start 2019-09
  33. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  34. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04974047Study sitePhase 2Start 2021-08
  35. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  36. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  37. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  38. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  39. Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal CancerStatus unknownNCT04426955Study sitePhase 3Start 2020-06
  40. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  41. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Study sitePhase 3Start 2020-02
  42. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  43. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  44. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03817567Study sitePhase 1/Phase 2Start 2018-07
  45. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  46. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  47. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
  48. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell CarcinomaCompletedNCT02395705Study sitePhase 3Start 2015-06
  49. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
  50. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)57
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. 223. CAMRELIZUMAB AND CHEMOTHERAPY AS NEOADJUVANT TREATMENT FOR LOCALLYADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)A SINGLE-ARM, PHASE II TRIAL2025Diseases of the Esophagusarticle
  3. 251. PRELIMINARY SURGICAL OUTCOMES FROM MULTICENTER, RANDOMIZED PHASE III TRIAL (SCIENCE): IMPACT OF NEOADJUVANT SINTILIMAB-BASED REGIMENS ON RESECTABLE LOCALLY ADVANCED ESCC2025Diseases of the Esophagusarticle
  4. 337. RETROSPECTIVE COHORT STUDY OF VIDEO- AND ROBOT-ASSISTED ESOPHAGECTOMY AFTER NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagusarticle
  5. 347. THE LYMPH NODE DISSECTION OF NO.106RECL WAS ASSOCIATED WITH BETTER LONG-TERM SURVIVAL FOR ESOPHAGEAL CANCER AFTER ROBOT-ASSISTED ESOPHAGECTOMY2025Diseases of the Esophagusarticle
  6. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagusarticle
  7. 379. HEALTH-RELATED QUALITY OF LIFE FOLLOWING ROBOTIC VERSUS THORACOSCOPIC ESOPHAGECTOMY: A PRESPECIFIED SECONDARY ANALYSIS OF THE MULTICENTER REVATE TRIAL2025Diseases of the Esophagusarticle
  8. 486eTiP Interim results and ctDNA biomarker analysis from the phase III SCIENCE trial: Neoadjuvant chemotherapy or chemoradiotherapy with/without sintilimab for resectable locally advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  9. 486eTiP Interim results and ctDNA biomarker analysis from the phase III SCIENCE trial: Neoadjuvant chemotherapy or chemoradiotherapy with/without sintilimab for resectable locally advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  10. 963P SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: Results from dose escalation study2025Annals of Oncologyarticle
  11. A Multi-Dimensional Deep Ensemble Learning Model Predicts Pathological Response and Treatment Outcomes to Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Pretreatment CT Images: A Multicenter, Retrospective Cohort 2025International Journal of Radiation Oncology*Biology*Physicsarticle
  12. Impact of muscle mass loss on survival during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma: A multi-center retrospective study in China (TIMES study).2025Journal of Clinical Oncologyarticle
  13. Knockdown of DNAJC12 slows tumor progression and affects tumor radiosensitivity in esophageal squamous cell carcinoma2025Molecular & cellular biomechanicsarticle
  14. Long-term outcomes of toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: Results from a phase II trial.2025Journal of Clinical Oncologyarticle
  15. Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced e2025Journal of Clinical Oncologyarticle
  16. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncologyconference-abstract
  17. 1414P Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II study2024Annals of Oncologyarticle
  18. 552. COMPARING ROBOTIC ESOPHAGECTOMY TO VIDEO-ASSISTED THORACOSCOPIC ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: RESULTS FROM THE REVATE RANDOMIZED CLINICAL TRIAL2024Diseases of the Esophagusarticle
  19. ALOX12B and PRMT5 inhibit stemness and EMT in esophageal squamous cell carcinoma by promoting decorin expression2024Research Squarepreprint
  20. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Researchconference-abstract
  21. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  22. Conversion surgery for tislelizumab combined chemotherapy for T4a/N3 esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.2024Journal of Clinical Oncologyconference-abstract
  23. Extracellular Hmgb1 Increases Radioresistance of Esophageal Squamous Cell Carcinoma Through Stabilizing Pd-L1 by Npm12024SSRN Electronic Journalpreprint
  24. Multimodality Deep Learning Radiomics Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  25. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint
  26. Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligometastasis at Initial Diagnosis2024International Journal of Radiation Oncology*Biology*Physicsarticle
  27. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncologyconference-abstract
  28. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncologyarticle
  29. 153. PROPENSITY MATCHING ANALYSIS OF NEOADJUVANT CHEMORADIOTHERAPY AND NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED ESCC2023Diseases of the Esophagusarticle
  30. 1558P Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial2023Annals of Oncologyarticle
  31. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncologyarticle
  32. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  33. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  34. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  35. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  36. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  37. Advantages of nasogastric tube feeding during neoadjuvant concurrent chemoradiotherapy for esophageal cancer: A retrospective study2023Radiation Medicine and Protectionarticle
  38. Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.2023Journal of Clinical Oncologyconference-abstract
  39. Deep learning-based prediction model for predicting the tumor origin of cancers of unknown primary.2023Journal of Clinical Oncologyconference-abstract
  40. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncologyconference-abstract
  41. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  42. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  43. CT-Based Deep Learning Model for Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Patients Received Concurrent Chemo-Radiotherapy: A Multicenter Study2022International Journal of Radiation Oncology*Biology*Physicsarticle
  44. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  45. Diagnostic efficacy of deep learning-based prediction of origin for patients with cancers of unknown primary.2022Journal of Clinical Oncologyconference-abstract
  46. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  47. Establishment of a risk model by integrating hypoxia genes in predicting prognosis of esophageal squamous cell carcinoma2022Research Squarepreprint
  48. Establishment of a risk model by integrating hypoxia genes in predicting prognosis of esophageal squamous cell carcinoma2022Research Squarepreprint
  49. High expression of PPFIA1 in human esophageal squamous cell carcinoma correlates with tumor progression and poor prognosis2022Research Squarepreprint
  50. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas2021Annals of Oncologyarticle
  51. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis2021International Journal of Radiation Oncology*Biology*Physicsarticle
  52. High Expression of PPFIA1 Is Associated With Tumor Progression and a Poor Prognosis in Esophageal Squamous Cell Carcinoma2021Research Squarepreprint
  53. Identification of a Hypoxia-Related Gene Signature and Establishment of a Nomogram for Predicting Prognosis in Esophageal Squamous Cell Carcinoma2021SSRN Electronic Journalpreprint
  54. LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, si2021Annals of Oncologyarticle
  55. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset
  56. Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell cancer.2021Journal of Clinical Oncologyconference-abstract
  57. The Prognostic Performance of Log Odds of Positive Lymph Nodes in Patients with Esophageal Squamous Cell Carcinoma: A Population Study of the US SEER Database and a Chinese Single-Institution Cohort2021SSRN Electronic Journalpreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 88 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
88
2021–2025
Trials led
37
any status, ClinicalTrials.gov
Open trials led
11
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 222220212022: 161620222023: 161620232024: 191920242025: 14142025

4 hospitals in Tianjin for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 20

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07475026

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  2. Recruiting
    Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07560488

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  3. Recruiting
    IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07799922

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  4. Recruiting
    Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07801287

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  5. Recruiting
    Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07840092

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  6. Recruiting
    Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06766643

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  7. Recruiting
    FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07012798

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  8. Recruiting
    Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07099274

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  9. Recruiting
    Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301399

    Age 17 years to 79 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  10. Not yet recruiting
    Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07847671

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  11. Not yet recruiting
    Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07157306

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  12. Recruiting
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07479485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou

  13. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin

  14. Recruiting
    HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06812039

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesFuzhou, Shanghai, Tianjin

  15. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  16. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  17. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  18. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  19. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  20. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led88
  1. LI-RADS nonradiation treatment response assessment version 2024: diagnostic performance in HCC treated with transarterial chemoembolization.2026European radiology
  2. Minimalistic Implant for Percutaneous Magnetic Hyperthermia-Based Combination Therapy of Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  3. Aristolochic acids-hijacked p53 promotes liver cancer cell growth by inhibiting ferroptosis.2025Acta pharmacologica SinicaFree full text
  4. Inhibition of nuclear receptor coactivator 5 overcomes acquired lenvatinib resistance driven by protein kinase B-mammalian target of rapamycin signaling in hepatocellular carcinoma.2025Anti-cancer drugsFree full text
  5. 18F-FDG PET/CT-based intratumoral and peritumoral radiomics combining ensemble learning for prognosis prediction in hepatocellular carcinoma: a multi-center study.2025BMC cancerFree full text
  6. Survival benefit of adjuvant chemotherapy and individualized prognosis in resected cHCC-CCA.2025Bioscience trends
  7. Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth.2025Cancer letters
  8. CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance.2025Cancer research
  9. Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  10. Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study.2025Clinical cancer research : an official journal of the American Association for Cancer Research
  11. Macrophage membrane-based biomimetic nanocarrier system for enhanced immune activation and combination therapy in liver cancer.2025Drug delivery and translational research
  12. Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.2025Frontiers in immunologyFree full text
  13. Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.2025Frontiers in immunologyFree full text
  14. Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.2025Frontiers in immunologyFree full text
  15. Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study.2025Hepatology international
  16. Efficacy and Safety of CT-guided Percutaneous Cryoablation for Hepatocellular Carcinoma at High-risk Sites.2024Academic radiology
  17. Bevacizumab induces ferroptosis and enhances CD8+ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9.2024Acta pharmacologica SinicaFree full text
  18. Artificial Intelligence-Driven Platform: Unveiling Critical Hepatic Molecular Alterations in Hepatocellular Carcinoma Development.2024Advanced healthcare materials
  19. CDCA8 Facilitates Tumor Proliferation and Predicts a Poor Prognosis in Hepatocellular Carcinoma.2024Applied biochemistry and biotechnology
  20. ARHGAP18 is Upregulated by Transcription Factor GATA1 Promotes the Proliferation and Invasion in Hepatocellular Carcinoma.2024Applied biochemistry and biotechnology
  21. 18F-FDG PET/CT-based habitat radiomics combining stacking ensemble learning for predicting prognosis in hepatocellular carcinoma: a multi-center study.2024BMC cancerFree full text
  22. Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression.2024BMC cancerFree full text
  23. From bioinformatics to clinical applications: a novel prognostic model of cuproptosis-related genes based on single-cell RNA sequencing data in hepatocellular carcinoma.2024BMC immunologyFree full text
  24. Sorafenib combined with TACE improves survival in patients with hepatocellular carcinoma with vascular invasion.2024Bioscience trends
  25. Large language model produces high accurate diagnosis of cancer from end-motif profiles of cell-free DNA.2024Briefings in bioinformaticsFree full text
  26. Language model enables end-to-end accurate detection of cancer from cell-free DNA.2024Briefings in bioinformaticsFree full text
  27. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.2024Cancer
  28. Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation.2024Cell reports. MedicineFree full text
  29. Integrated single-cell and bulk transcriptome analysis of R-loop score-based signature with regard to immune microenvironment, lipid metabolism and prognosis in HCC.2024Frontiers in immunologyFree full text
  30. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.2024Frontiers in immunologyFree full text
  31. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma.2024Hepatology internationalFree full text
  32. Dual-Drug Loaded Nanobubbles Combined with Sonodynamic and Chemotherapy for Hepatocellular Carcinoma Therapy.2024International journal of nanomedicineFree full text
  33. Liver cancer-specific mutations in functional domains of ADAR2 lead to the elevation of coding and non-coding RNA editing in multiple tumor-related genes.2024Molecular genetics and genomics : MGG
  34. Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma.2024World journal of gastroenterologyFree full text
  35. Predictive Factors of Treatment Outcomes After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in the Hepatocaval Confluence: A Propensity Score Matching Analysis.2023Academic radiology
  36. Aspirin modulates succinylation of PGAM1K99 to restrict the glycolysis through NF-κB/HAT1/PGAM1 signaling in liver cancer.2023Acta pharmacologica SinicaFree full text
  37. Heat shock protein family A member 8 serving as a co-activator of transcriptional factor ETV4 up-regulates PHLDA2 to promote the growth of liver cancer.2023Acta pharmacologica SinicaFree full text
  38. Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-κB p65-activated SLC7A11 transcription.2023Acta pharmacologica SinicaFree full text
  39. The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  40. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.2023AgingFree full text
  41. Fc fragment of IgG binding protein is correlated with immune infiltration levels in hepatocellular carcinoma.2023Biomolecules & biomedicineFree full text
  42. Comparison of the long-term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation.2023Cancer medicineFree full text
  43. Pan-cancer analysis of cuproptosis-promoting gene signature from multiple perspectives.2023Clinical and experimental medicine
  44. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression.2023Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  45. Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT/mTOR pathway.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  46. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.2023Frontiers in immunologyFree full text
  47. Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC.2023Hepatology (Baltimore, Md.)Free full text
  48. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation.2023Histopathology
  49. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.2023Neoplasma
  50. miR-4270 suppresses hepatocellular carcinoma progression by inhibiting DNMT3A-mediated methylation of HGFAC promoter.2023PeerJFree full text
  51. IFN-α inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver.2022Acta pharmacologica SinicaFree full text
  52. Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma.2022BMC cancerFree full text
  53. Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  54. Screening for Lipid-Metabolism-Related Genes and Identifying the Diagnostic Potential of ANGPTL6 for HBV-Related Early-Stage Hepatocellular Carcinoma.2022BiomoleculesFree full text
  55. Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma.2022Bioscience trends
  56. PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma.2022Cell death & diseaseFree full text
  57. DNAJC24 is a potential therapeutic target in hepatocellular carcinoma through affecting ammonia metabolism.2022Cell death & diseaseFree full text
  58. Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer.2022Cellular oncology (Dordrecht, Netherlands)Free full text
  59. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  60. Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma.2022Gastroenterology
  61. A nomogram based on a three pyroptosis gene model and clinical parameters for predicting prognosis of hepatocellular carcinoma.2022Gene
  62. Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden.2022Human cell
  63. Targeting delivery of synergistic dual drugs with elastic PEG-modified multi-functional nanoparticles for hepatocellular carcinoma therapy.2022International journal of pharmaceutics
  64. LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma.2022MedicineFree full text
  65. Decreased expression of SVEP1 is closely related to a cancer stem cell-like phenotype and poor prognosis in hepatocellular carcinoma.2022Neoplasma
  66. Mechanism of miR-424-5p promoter methylation in promoting epithelial-mesenchymal transition of hepatocellular carcinoma cells.2022The Kaohsiung journal of medical sciencesFree full text
  67. Hepatitis B Virus X Protein Modulates Chemokine CCL15 Upregulation in Hepatocellular Carcinoma.2021Anti-cancer agents in medicinal chemistry
  68. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.2021BMC cancerFree full text
  69. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.2021BioMed research internationalFree full text
  70. Aspirin modulates 2-hydroxyisobutyrylation of ENO1K281 to attenuate the glycolysis and proliferation of hepatoma cells.2021Biochemical and biophysical research communications
  71. Replication Factor C4 in human hepatocellular carcinoma: A potent prognostic factor associated with cell proliferation.2021Bioscience trends
  72. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.2021Bioscience trends
  73. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China.2021Bioscience trends
  74. MCM4 in human hepatocellular carcinoma: a potent prognostic factor associated with cell proliferation.2021Bioscience trends
  75. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data.2021British journal of cancerFree full text
  76. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.2021Cancer gene therapy
  77. Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.2021Cancer letters
  78. DTYMK promote hepatocellular carcinoma proliferation by regulating cell cycle.2021Cell cycle (Georgetown, Tex.)Free full text
  79. PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway.2021Cell death & diseaseFree full text
  80. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway.2021Cell death & diseaseFree full text
  81. MicroRNA-361 suppresses the biological processes of hepatic stellate cells in HBV-relative hepatic fibrosis by NF-kappaB p65.2021Cells & development
  82. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.2021Cellular oncology (Dordrecht, Netherlands)Free full text
  83. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.2021European radiology
  84. Identifying the biomarkers and pathways associated with hepatocellular carcinoma based on an integrated analysis approach.2021Liver international : official journal of the International Association for the Study of the Liver
  85. LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.2021Molecular metabolismFree full text
  86. Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness.2021Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  87. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: in patients with different clinicopathologic characteristics.2021World journal of surgical oncologyFree full text
  88. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II.2021Yonsei medical journalFree full text
Chinese-language papers (not in the count)3
  1. [The influence of knocking down the expression of low-density lipoprotein receptor associated proteins on the vascular abnormalities in hepatocellular carcinoma and its mechanisms].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Changes and challenges of surgical treatment strategy for hepatocellular carcinoma].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Application of superb microvascular imaging in focal liver lesions].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status66
  1. A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Lead sponsorPhase 3Start 2026-06
  2. Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingNCT07560488Lead sponsorPhase 2Start 2026-03
  3. Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCCRecruitingNCT07801287Lead sponsorPhase 2Start 2026-09
  4. Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCCNot yet recruitingNCT07847671Lead sponsorPhase 2Start 2026-10
  5. IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor ThrombusRecruitingNCT07799922Lead sponsorN/AStart 2026-05
  6. Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular CarcinomaRecruitingNCT07840092Lead sponsorStart 2026-10
  7. Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular CarcinomaRecruitingNCT07099274Lead sponsorPhase 2Start 2025-08
  8. FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular CarcinomaRecruitingNCT07012798Lead sponsorPhase 2Start 2025-09
  9. Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver CancerRecruitingNCT06766643Lead sponsorPhase 2Start 2025-01
  10. Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07157306Lead sponsorPhase 2Start 2025-09
  11. Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyRecruitingNCT06301399Lead sponsorPhase 2Start 2024-03
  12. Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVIActive, not recruitingNCT07658105Lead sponsorPhase 2Start 2026-06
  13. Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma(uHCC).Status unknownNCT06375486Lead sponsorPhase 2Start 2024-03
  14. Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular CarcinomaSuspendedNCT06405061Lead sponsorPhase 2Start 2024-05
  15. Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyStatus unknownNCT05856864Lead sponsorPhase 1Start 2024-06
  16. HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular CarcinomaStatus unknownNCT05864755Lead sponsorPhase 2Start 2023-06
  17. Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.CompletedNCT05807776Lead sponsorPhase 2Start 2023-04
  18. Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT06370065Lead sponsorPhase 2Start 2023-04
  19. HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular CarcinomaStatus unknownNCT05821361Lead sponsorPhase 2Start 2023-08
  20. A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular CarcinomaActive, not recruitingNCT05644379Lead sponsorPhase 1Start 2022-11
  21. Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaStatus unknownNCT05616390Lead sponsorPhase 2Start 2022-11
  22. HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaActive, not recruitingNCT05621499Lead sponsorN/AStart 2022-12
  23. Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaStatus unknownNCT05519410Lead sponsorPhase 2Start 2022-08
  24. HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCCStatus unknownNCT05029973Lead sponsorPhase 2Start 2021-05
  25. Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaStatus unknownNCT04834986Lead sponsorPhase 2Start 2021-04
  26. Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaCompletedNCT04701060Lead sponsorPhase 2Start 2021-01
  27. TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant TumorsStatus unknownNCT06487663Lead sponsorN/AStart 2020-10
  28. Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver CancerActive, not recruitingNCT07298538Lead sponsorStart 2019-01
  29. PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCCStatus unknownNCT04273100Lead sponsorPhase 2Start 2019-11
  30. Study of Apatinib Combined With TACE in Advance Hepatocellular CarcinomaStatus unknownNCT03398122Lead sponsorN/AStart 2017-11
  31. Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)Status unknownNCT03046979Lead sponsorPhase 2Start 2016-12
  32. Metformin Plus Sorafenib for Advanced HCCStatus unknownNCT02672488Lead sponsorPhase 2Start 2015-12
  33. Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnifeStatus unknownNCT02363218Lead sponsorPhase 2Start 2014-05
  34. A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular CarcinomaStatus unknownNCT01758679Lead sponsorPhase 4Start 2012-01
  35. Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular CarinomasStatus unknownNCT01393093Lead sponsorN/AStart 2011-03
  36. Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)Status unknownNCT01393197Lead sponsorN/AStart 2011-03
  37. Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional TherapyStatus unknownNCT05975463Lead (inferred)Phase 2Start 2023-09
  38. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  39. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingNCT07479485Study sitePhase 1/Phase 2Start 2026-04
  40. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  41. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  42. HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingNCT06812039Study sitePhase 2Start 2025-01
  43. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular CarcinomaNot yet recruitingNCT06779461Study sitePhase 3Start 2025-01
  44. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  45. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  46. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  47. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  48. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  49. Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)Status unknownNCT05594927Study sitePhase 3Start 2022-12
  50. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  51. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Study sitePhase 2Start 2021-01
  52. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  53. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Study sitePhase 3Start 2021-04
  54. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  55. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Study sitePhase 3Start 2021-04
  56. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  57. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  58. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07
  59. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  60. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  61. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  62. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  63. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05
  64. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Study sitePhase 1Start 2015-07
  65. Urea Cream Treatment Sorafenib-Associated HSFR in HCCCompletedNCT01934829Study sitePhase 2Start 2009-07
  66. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 78 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.8%.

Papers led
78
2021–2025
Trials led
36
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
13
led by another institution
Papers led per year
2021: 151520212022: 8820222023: 202020232024: 141420242025: 19192025

3 hospitals in Tianjin for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 19

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07183150

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  2. Recruiting
    A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06506292

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  3. Recruiting
    Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06560528

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  4. Recruiting
    A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer
    Phase
    N/A
    Started
    2021-01
    Registry
    NCT04843215

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  5. Not yet recruiting
    Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06454435

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  6. Enrolling by invitation
    Laparoscopic Staging for Stage III Gastric Cancer
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07533825

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  7. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  8. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  9. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  10. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  11. Recruiting
    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07070232

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Hangzhou, Tianjin, Wuhan

  12. Recruiting
    A Study of LY4257496 in Participants With Cancer (OMNIRAY)
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07114601

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  13. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  14. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  15. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  16. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  17. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  18. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  19. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImaging & AIEarly detection & endoscopy
Departments in papersMedical oncologyPathology / laboratory medicineGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led78
  1. Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.2026International journal of cancer
  2. Elucidating the molecular mechanisms of the mongolian medicine Ana Gaqi Nari in gastric cancer treatment through a multi-omics-guided experimental validation.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center.2025BMC cancerFree full text
  4. Construction and validation of a lactylation-based gene signature for prognostic assessment and immune infiltration analysis in gastric adenocarcinoma.2025BMC medical genomicsFree full text
  5. Inhibitory effects of circR-127aa on gastric cancer progression and tumor growth.2025Cellular signalling
  6. The clinical significance assessment of the transverse lymph node metastasis in gastric cancer: The establishment and validation of nomogram from a single clinical medical center.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. Spectral CT-based nomogram for preoperative prediction of Lauren classification in locally advanced gastric cancer: a prospective study.2025European radiology
  8. Neoadjuvant serplulimab and SOX chemotherapy for locally advanced gastric cancer: pathological responses and systemic immune signatures from a phase II trial.2025Frontiers in immunologyFree full text
  9. Functional and clinical validation of tsRNA-defined molecular subtypes guides precision therapy in gastric cancer.2025Frontiers in immunologyFree full text
  10. Identification of prognosis and therapy related intratumoral microbiome and immune signatures in gastric cancer.2025Frontiers in immunologyFree full text
  11. Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  12. Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.2025International journal of cancerFree full text
  13. Artificial neural network model enhancing the accuracy of clinical evaluation for high-risk population of lymph node metastasis in non-intestinal type early gastric cancer: a multicenter real-world study in China.2025International journal of surgery (London, England)Free full text
  14. Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer.2025Investigational new drugs
  15. Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection.2025JCO precision oncology
  16. Clinicopathological Characteristics and Perioperative Treatment of Epstein-Barr Virus-Associated Gastric Cancer: A Retrospective Study.2025Oncology
  17. Exosomal miR-224-3p promotes lymphangiogenesis and lymph node metastasis by targeting GSK3B in gastric cancer.2025Oncology researchFree full text
  18. Pan-cancer landscape of ITGAV and its potential role in gastric cancer.2025Scientific reportsFree full text
  19. Risk assessment of lymph node metastasis in early gastric cancer patients with vagus nerve-preserving gastrectomy: A multiple centers potential analysis in China.2025Surgery
  20. Examining more than 35 lymph nodes improves the staging and survival in resectable advanced gastric cancer: a multi-institutional study in China.2025Surgery today
  21. Glycosylation Triggers Cathepsin D Maturation and Secretion to Promote Gastric Cancer Development.2025The American journal of pathology
  22. Comparison of short‑term outcomes and 3-year overall survival between robotic and laparoscopic gastrectomy for gastric cancer: a propensity score matching analysis.2024Acta chirurgica Belgica
  23. ASO Author Reflections: Optimizing Therapy Strategies for Early Gastric Cancer by Leveraging Innovative Predictors of Lymph Node Involvement.2024Annals of surgical oncology
  24. The Key Role of Tumor Budding in Predicting the Status of Lymph Node Involvement in Early Gastric Cancer Patients: A Clinical Multicenter Validation in China.2024Annals of surgical oncology
  25. A Novel lncRNA FUAT1/TNS4 Axis Confers Chemoresistance by Suppressing Reactive Oxygen Species-Mediated Apoptosis in Gastric Cancer.2024Antioxidants & redox signaling
  26. Biomarkers of lipid metabolism in gastric cancer: a case control study.2024BMC cancerFree full text
  27. EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8/NF-κB signalling activation independent of hydroxylase activity.2024British journal of cancerFree full text
  28. From complexity to clarity: development of CHM-FIEFP for predicting effective components in Chinese herbal formulas by using big data.2024Cancer biology & medicineFree full text
  29. Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study.2024Cancer immunology, immunotherapy : CIIFree full text
  30. ACAT2 suppresses the ubiquitination of YAP1 to enhance the proliferation and metastasis ability of gastric cancer via the upregulation of SETD7.2024Cell death & diseaseFree full text
  31. DNA methylation-mediated suppression of TUSC1 expression regulates the malignant progression of esophagogastric junction cancer.2024Clinical epigeneticsFree full text
  32. Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells.2024Experimental cell research
  33. Establishment and validation of a risk score model based on EUS: assessment of lymph node metastasis in early gastric cancer.2024Gastrointestinal endoscopy
  34. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy.2024Journal for immunotherapy of cancerFree full text
  35. Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells.2024Oncology researchFree full text
  36. Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.2023BMC cancerFree full text
  37. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.2023BMC cancerFree full text
  38. Cohort profile: design and methods of the Chinese colorectal, breast, lung, liver, and stomach cancer screening trial (C-BLAST).2023Cancer biology & medicineFree full text
  39. Construction and testing of a risk prediction classifier for cardia carcinoma.2023Carcinogenesis
  40. The microprotein encoded by exosomal lncAKR1C2 promotes gastric cancer lymph node metastasis by regulating fatty acid metabolism.2023Cell death & diseaseFree full text
  41. SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.2023Cell death & diseaseFree full text
  42. Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target.2023Clinical and experimental medicine
  43. E3 ubiquitin ligase RNF180 prevents excessive PCDH10 methylation to suppress the proliferation and metastasis of gastric cancer cells by promoting ubiquitination of DNMT1.2023Clinical epigeneticsFree full text
  44. Inactivation of ZSCAN18 by promoter hypermethylation drives the proliferation via attenuating TP53INP2-mediated autophagy in gastric cancer cells.2023Clinical epigeneticsFree full text
  45. DEPTOR as a novel prognostic marker inhibits the proliferation via deactivating mTOR signaling pathway in gastric cancer cells.2023Experimental cell research
  46. Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals.2023Helicobacter
  47. Clinicopathological and genetic characteristics of gastric neuroendocrine tumour (NET) G3 and comparisons with neuroendocrine carcinoma and NET G2.2023Histopathology
  48. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation.2023Histopathology
  49. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.2023Immunotherapy
  50. Development and validation of prognostic model based on extragastric lymph nodes metastasis and lymph node ratio in node-positive gastric cancer: a retrospective cohort study based on a multicenter database.2023International journal of surgery (London, England)Free full text
  51. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.2023Journal of advanced researchFree full text
  52. circIPO7 dissociates caprin-1 from ribosomes and inhibits gastric cancer cell proliferation by suppressing EGFR and mTOR.2023OncogeneFree full text
  53. EDIL3 is a potential prognostic biomarker that correlates with immune infiltrates in gastric cancer.2023PeerJFree full text
  54. Imaging lymph node regression can predict the pathological tumor regression grade in gastric cancer after neoadjuvant treatment.2023Surgery
  55. ALDOC regulated the biological function and immune infiltration of gastric cancer cells.2023The international journal of biochemistry & cell biology
  56. Cancer-suppressing miR-520-3p gene inhibits proliferation, migration, and invasion of gastric cancer cells through targeted regulation of KLF7.2022Bulletin du cancer
  57. Exosomal miR-155 from gastric cancer induces cancer-associated cachexia by suppressing adipogenesis and promoting brown adipose differentiation via C/EPBβ.2022Cancer biology & medicineFree full text
  58. The Number of Positive Tumor Markers (NPTM) Achieves Higher Value in the Prognosis Prediction of Gastric Cancer.2022Disease markersFree full text
  59. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.2022International journal of cancerFree full text
  60. TAZ promotes vasculogenic mimicry in gastric cancer through the upregulation of TEAD4.2022Journal of gastroenterology and hepatology
  61. Role of non-coding RNA in immune microenvironment and anticancer therapy of gastric cancer.2022Journal of molecular medicine (Berlin, Germany)
  62. Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms.2022Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  63. Risk assessment of lymph node metastasis in early gastric cancer: Establishment and validation of a Seven-point scoring model.2022Surgery
  64. A CT-based Radiomics Model for Prediction of Lymph Node Metastasis in Early Stage Gastric Cancer.2021Academic radiology
  65. Gastric cancer derived exosomes mediate the delivery of circRNA to promote angiogenesis by targeting miR-29a/VEGF axis in endothelial cells.2021Biochemical and biophysical research communications
  66. Prospective study of the effect of ERAS on postoperative recovery and complications in patients with gastric cancer.2021Cancer biology & medicineRCTFree full text
  67. Chemotoxicity-induced exosomal lncFERO regulates ferroptosis and stemness in gastric cancer stem cells.2021Cell death & diseaseFree full text
  68. circEVI5 acts as a miR-4793-3p sponge to suppress the proliferation of gastric cancer.2021Cell death & diseaseFree full text
  69. Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer.2021Cell death & diseaseFree full text
  70. DNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells.2021Cell death & diseaseFree full text
  71. Alterations in mucosa-associated microbiota in the stomach of patients with gastric cancer.2021Cellular oncology (Dordrecht, Netherlands)Free full text
  72. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.2021Frontiers in immunologyFree full text
  73. Development of a two-circular RNA panel as potential prognostic biomarker for gastric cancer.2021Journal of translational medicineFree full text
  74. VRK1 promotes proliferation, migration, and invasion of gastric carcinoma cells by activating β-catenin.2021Neoplasma
  75. Well differentiated carcinoma with a poor prognosis: a retrospective analysis of papillary gastric adenocarcinoma.2021Surgery today
  76. Effects of a high body mass index on the short-term outcomes and prognosis after radical gastrectomy.2021Surgery today
  77. Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China.2021Surgery today
  78. Clinical features & treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma.2021The Indian journal of medical researchFree full text
Chinese-language papers (not in the count)12
  1. [Cytokeratin (pan)-positive EWSR1/FUS::CREB fusion malignant tumor in abdominopelvic cavity: a clinicopathological and molecular analysis of four cases].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Patterns of lymph node metastasis and prognosis in locally-advanced gastric cancer after neoadjuvant immunotherapy combined with chemotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Surgical strategies of radical gastrectomy for gastric cancer in the era of immunotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [A 30-year review of gastric cancer surgery: China has achieved leapfrog leadership].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Quality control of lymph node dissection for locally advanced gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Prognostic value of a predictive model comprising preoperative inflammatory response and nutritional indexes in patients with gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Differences in clinicopathological features, gene mutations, and prognosis between primary gastric and intestinal gastrointestinal stromal tumors in 1061 patients].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Clinical controversy and research thoughts on lymphadenectomy of gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Primary pancreatic adenocarcinoma with enteroblastic differentiation: report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  10. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [Progress in conversion therapy for stage IV gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status73
  1. Laparoscopic Staging for Stage III Gastric CancerEnrolling by invitationNCT07533825Lead sponsorN/AStart 2025-02
  2. The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric CancerRecruitingNCT07183150Lead sponsorStart 2025-08
  3. A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)RecruitingNCT06506292Lead sponsorPhase 2Start 2024-07
  4. Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 OverexpressionRecruitingNCT06560528Lead sponsorPhase 2Start 2024-09
  5. Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric CancerNot yet recruitingNCT06454435Lead sponsorPhase 2Start 2024-06
  6. A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric CancerRecruitingNCT04843215Lead sponsorN/AStart 2021-01
  7. A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC PatientsCompletedNCT06339307Lead sponsorStart 2024-02
  8. Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric CancerStatus unknownNCT06102772Lead sponsorStart 2023-11
  9. Fruquintinib Combined With TAS102 for Advanced Gastric CancerStatus unknownNCT06102785Lead sponsorStart 2023-11
  10. Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric CancerStatus unknownNCT05974059Lead sponsorPhase 2Start 2023-08
  11. Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ CancerStatus unknownNCT05853172Lead sponsorPhase 2Start 2023-03
  12. Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody FailedStatus unknownNCT06102759Lead sponsorStart 2023-11
  13. Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced DiarrheaCompletedNCT07460596Lead sponsorPhase 2Start 2023-01
  14. Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side AnastomosisStatus unknownNCT05812495Lead sponsorN/AStart 2023-03
  15. Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction CancerStatus unknownNCT06496789Lead sponsorPhase 2Start 2023-05
  16. Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsStatus unknownNCT06383559Lead sponsorPhase 2Start 2023-12
  17. The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric CancerStatus unknownNCT06033482Lead sponsorStart 2023-06
  18. A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative SurgeryCompletedNCT06023966Lead sponsorStart 2023-09
  19. Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus unknownNCT05942573Lead sponsorPhase 2Start 2022-12
  20. A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal MalignanciesActive, not recruitingNCT06997302Lead sponsorN/AStart 2022-01
  21. Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric CancerStatus unknownNCT04982939Lead sponsorPhase 2Start 2021-06
  22. Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y ReconstructionStatus unknownNCT04801459Lead sponsorN/AStart 2021-04
  23. Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsStatus unknownNCT05221775Lead sponsorPhase 1Start 2021-11
  24. Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric CancerCompletedNCT04354662Lead sponsorPhase 2Start 2020-05
  25. Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric CancerStatus unknownNCT05228743Lead sponsorN/AStart 2020-09
  26. Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric CancerStatus unknownNCT04267549Lead sponsorPhase 2Start 2019-05
  27. Chemotherapy Combined With Apatinib and PD-1 AntibodyCompletedNCT05025033Lead sponsorPhase 2Start 2019-05
  28. A Trial of Total Versus Partial Omentectomy for Advanced Gastric Cancer in GastrectomyStatus unknownNCT04108494Lead sponsorN/AStart 2019-01
  29. The Criteria for Lymph Node Sorting for Pathological Examination in Gastric CancerStatus unknownNCT03478449Lead sponsorN/AStart 2018-04
  30. An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and GastricStatus unknownNCT03285906Lead sponsorPhase 2/Phase 3Start 2017-03
  31. A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant ChemotherapyStatus unknownNCT02776527Lead sponsorPhase 4Start 2016-04
  32. A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric CancerStatus unknownNCT02272894Lead sponsorStart 2014-07
  33. Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric CancerStatus unknownNCT02024438Lead sponsorPhase 3Start 2013-12
  34. Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer PatientsStatus unknownNCT01618474Lead sponsorPhase 2Start 2012-05
  35. Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric CancerStatus unknownNCT01637805Lead sponsorPhase 1Start 2012-05
  36. Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 DiabetesStatus unknownNCT01637350Lead sponsorStart 2012-08
  37. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  38. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  39. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  40. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsRecruitingNCT07070232Study sitePhase 1/Phase 2Start 2025-08
  41. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Study sitePhase 2Start 2025-12
  42. A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Study sitePhase 1Start 2025-08
  43. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  44. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  45. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  46. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Study sitePhase 1/Phase 2Start 2024-06
  47. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  48. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  49. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  50. Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric JunctionActive, not recruitingNCT06576921Study sitePhase 2Start 2024-11
  51. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  52. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  53. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  54. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  55. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingNCT05382364Study sitePhase 1Start 2022-06
  56. Study of ESG401 in Adults With Solid TumorsCompletedNCT04892342Study sitePhase 1/Phase 2Start 2021-09
  57. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  58. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionCompletedNCT04661150Study sitePhase 2Start 2021-03
  59. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Study sitePhase 2Start 2021-08
  60. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  61. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Study sitePhase 1Start 2020-07
  62. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  63. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  64. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  65. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  66. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  67. Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable FactorStatus unknownNCT03399253Study sitePhase 2/Phase 3Start 2017-12
  68. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)CompletedNCT02745509Study siteN/AStart 2016-03
  69. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  70. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  71. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  72. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma SurgeryStatus unknownNCT02130752Study siteN/AStart 2014-10
  73. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Tianjin for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. Yap Expression Is Closely Related to Tumor Angiogenesis and Poor Prognosis in Hepatoblastoma.2022Fetal and pediatric pathology
Earlier papers (2016–2020)1
  1. Adult hepatoblastoma: a review of 47 cases.2018ANZ journal of surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Tianjin for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 18 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 5520222023: 3320232024: 2220242025: 662025

15 hospitals in Tianjin for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led18
  1. SOCS1 depletion drives osteosarcoma stemness and chemoresistance by suppressing ACTN4 degradation.2026Acta pharmacologica Sinica
  2. CT-assessed pectoralis major muscle measurements as risk factors for low neoadjuvant chemotherapy efficacy in osteosarcoma: a retrospective study.2025BMC medical imaging
  3. METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1.2025Cancer letters
  4. Assessing the current molecular understanding of therapeutic targets in osteosarcoma.2025Expert opinion on therapeutic targets
  5. Integrated multi-omics reveals GABARAP-mediated mitophagy and pyruvate metabolism as key drivers of osteosarcoma progression.2025Frontiers in immunology
  6. Benchmarking PathCLIP for Pathology Image Analysis.2025Journal of imaging informatics in medicine
  7. CD93 aggravates cell proliferation, angiogenesis and immune escape in osteosarcoma through triggering the PI3K/AKT pathway.2025Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  8. Construction of an oxidative phosphorylation-related gene signature for predicting prognosis and identifying immune infiltration in osteosarcoma.2024Aging
  9. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors.2024International journal of cancer
  10. Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: a single-center experience of 11 years in Tianjin, China.2023BMC cancer
  11. A1BG-AS1 promotes the biological functions of osteosarcoma cells via regulating the microRNA-148a-3p/USP22 axis and stabilizing the expression of SIRT1 through deubiquitinase function.2023Expert opinion on therapeutic targets
  12. Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma.2023PloS one
  13. Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy.2022Aging
  14. Polygonum cuspidatum inhibits the growth of osteosarcoma cells via impeding Akt/ERK/EGFR signaling pathways.2022Bioengineered
  15. EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway.2022Clinical and experimental pharmacology & physiology
  16. Identification of B cell marker genes based on single-cell sequencing to establish a prognostic model and identify immune infiltration in osteosarcoma.2022Frontiers in immunology
  17. Risk and Prognostic Factors for Different Organ Metastasis in Primary Osteosarcoma: A Large Population-Based Analysis.2022Orthopaedic surgery
  18. Homogenous and Heterogenous Prognostic Factors for Patients with Bone Sarcoma.2021Orthopaedic surgery
Earlier papers (2016–2020)9
  1. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.2020Cancer biology & medicine
  2. SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells.2019Biological chemistry
  3. Lung metastases at the initial diagnosis of high-grade osteosarcoma: prevalence, risk factors and prognostic factors. A large population-based cohort study.2019Sao Paulo medical journal = Revista paulista de medicina
  4. Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China.2019Scientific reports
  5. ONZIN Upregulation by Mutant p53 Contributes to Osteosarcoma Metastasis Through the CXCL5-MAPK Signaling Pathway.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  6. Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV.2018International journal of oncology
  7. Downregulation of lncRNA H19 inhibits migration and invasion of human osteosarcoma through the NF-κB pathway.2018Molecular medicine reports
  8. Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.2017Oncotarget
  9. Coexpression of CXCR4 and MMP9 predicts lung metastasis and poor prognosis in resected osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
All its trials on ClinicalTrials.gov, any status3
  1. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06
  2. TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid TumorsTerminatedNCT06438783Study sitePhase 1Start 2024-02
  3. IBI188 Combination Therapy in Solid TumorsTerminatedNCT04861948Study sitePhase 1Start 2021-05

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Tianjin for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 21 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
21
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 7720222023: 6620232024: 3320242025: 332025

11 hospitals in Tianjin for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07318831

    Age 0 years to 18 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  2. Recruiting
    APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05701306

    Age 5 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Wuhan

  3. Recruiting
    TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
    Phase
    Phase 1
    Started
    2022-12
    Registry
    NCT05562024

    Age 1 year to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesJinan, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led21
  1. Single-Cell Profiling of the Microenvironment in High-Risk Neuroblastoma.2025IUBMB life
  2. Autophagy inhibition amplifies anti-tumor immunity effect of dinutuximab beta on neuroblastoma via the VEGFR/AKT/mTOR and ROS/NF-κB pathways.2025International immunopharmacology
  3. PLK4 as a Key Regulator of Neuroblastoma Differentiation and a Promising Therapeutic Target.2025International journal of biological sciences
  4. Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.2024BMC cancer
  5. A mitochondria-related genes associated neuroblastoma signature - based on bulk and single-cell transcriptome sequencing data analysis, and experimental validation.2024Frontiers in immunology
  6. Prognostic significance of migrasomes in neuroblastoma through machine learning and multi-omics.2024Scientific reports
  7. Functionalized GD2 Electrochemical Immunosensor to Diagnose Minimum Residual Disease of Bone Marrow in Neuroblastoma Effectively.2023Biosensors
  8. Integrating Bulk-seq and Single-cell-seq Reveals Estrogen and MAPK Pathways Associating with Neuroblastoma Outcome.2023Cancer control : journal of the Moffitt Cancer Center
  9. Optimal combination of MYCN differential gene and cellular senescence gene predicts adverse outcomes in patients with neuroblastoma.2023Frontiers in immunology
  10. Identification of NCAPG as an Essential Gene for Neuroblastoma Employing CRISPR-Cas9 Screening Database and Experimental Verification.2023International journal of molecular sciences
  11. N6-methyladenosine-mediated overexpression of long noncoding RNA ADAMTS9-AS2 triggers neuroblastoma differentiation via regulating LIN28B/let-7/MYCN signaling.2023JCI insight
  12. Integrating bulk-seq and single-cell-seq reveals disulfidptosis potential index associating with neuroblastoma prognosis and immune infiltration.2023Journal of cancer research and clinical oncology
  13. Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma.2022Clinical cancer research : an official journal of the American Association for Cancer Research
  14. A novel ganglioside-related risk signature can reveal the distinct immune landscape of neuroblastoma and predict the immunotherapeutic response.2022Frontiers in immunology
  15. Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients.2022Frontiers in immunology
  16. Analysis of the efficacy of autologous peripheral blood stem cell transplantation in high-risk neuroblastoma.2022International journal of medical sciences
  17. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma.2022Journal of experimental & clinical cancer research : CR
  18. Salsolinol Induces Parkinson's Disease Through Activating NLRP3-Dependent Pyroptosis and the Neuroprotective Effect of Acteoside.2022Neurotoxicity research
  19. The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma.2022The British journal of radiology
  20. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.2021International journal of medical sciences
  21. Early Decline of Neuron-Specific Enolase during Neuroblastoma Chemotherapy is a Predictive Factor of Clinical Outcome.2021Pediatric hematology and oncology
Earlier papers (2016–2020)6
  1. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.2018Cell death & disease
  2. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.2018Journal of pediatric hematology/oncology
  3. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.2017Oncotarget
  4. A single center clinical analysis of children with high-risk neuroblastoma.2017Oncotarget
  5. Research progress of neuroblastoma related gene variations.2017Oncotarget
  6. Ultrasound-guided core needle biopsy in the diagnosis of neuroblastic tumors in children: a retrospective study on 83 cases.2017Pediatric surgery international
All its trials on ClinicalTrials.gov, any status4
  1. Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in ChildrenRecruitingNCT07318831Lead sponsorPhase 2Start 2026-01
  2. APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsRecruitingNCT05701306Study sitePhase 1/Phase 2Start 2023-02
  3. TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory NeuroblastomaRecruitingNCT05562024Study sitePhase 1Start 2022-12
  4. Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk NeuroblastomaCompletedNCT05373901Study sitePhase 1Start 2022-06

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Tianjin for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors.2024International journal of cancer
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's SarcomaCompletedNCT05046314Study sitePhase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 10 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.6%.

Papers led
10
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 1120232024: 1120242025: 112025

5 hospitals in Tianjin for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07114432

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  2. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  3. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  4. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  6. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsRelapse & resistanceDiagnosis, MRD & risk

Over half of these papers are lab or animal studies.

Papers it led10
  1. Serum heat shock protein family A member 9 protein as a biomarker for bortezomib resistance and poor prognosis in patients with multiple myeloma.2026Anti-cancer drugsFree full text
  2. HRP2 regulating MICU1-mediated Ca2+ overload to dictate chemoresistance of multiple myeloma.2025Neoplasia (New York, N.Y.)Free full text
  3. Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis.2024Hematology (Amsterdam, Netherlands)
  4. Influence of diabetes mellitus on the biochemical parameters and outcomes of multiple myeloma.2023Hematology (Amsterdam, Netherlands)
  5. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.2022Carcinogenesis
  6. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.2022Clinical and translational medicineFree full text
  7. Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma.2022Oncogene
  8. Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation.2022The Journal of clinical investigationFree full text
  9. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.2021Nature communicationsFree full text
  10. Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.2021OncogeneFree full text
All its trials on ClinicalTrials.gov, any status23
  1. RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple MyelomaNot yet recruitingNCT07114432Lead sponsorPhase 1Start 2025-08
  2. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06
  5. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Study sitePhase 2Start 2022-04
  6. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  7. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  8. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  9. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  10. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  11. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  12. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  13. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  14. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04557098Study sitePhase 2Start 2020-09
  15. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  16. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  17. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  18. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10
  19. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  20. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  21. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Study sitePhase 3Start 2015-10
  22. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  23. A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersCompletedNCT01524978Study sitePhase 2Start 2012-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Tianjin for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

天津医科大学肿瘤医院

Tianjin Medical University Cancer Institute & Hospital

天津

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Hospital; Tianjin Cancer Institute; Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital; Tianjin Medical University Cancer Hospital and Institute; Tianjin Cancer Institute & Hospital; Tianjin Cancer Hospital Airport Branch

Suggest a correctionDownload the data